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Abstract 
UTILITY OF APPARENT DIFFUSION COEFFICIENTS IN THE EVALUATION OF PRIMARY 
CENTRAL NERVOUS SYSTEM LYMPHOMA. 
John W. Gilbert1, Joachim M. Baehring2, Susanne Barth2, Ephraim P. Hochberg3, Fred H. Hochberg4, 
and Robert K. Fulbright (Sponsor)1 
1Department of Diagnostic Radiology, Yale School of Medicine, New Haven, CT 
2Departments of Neurology, Neurosurgery, and Internal Medicine, Yale School of Medicine, New Haven, CT 
3Department of Internal Medicine, Massachusetts General Hospital, Boston, MA 
4Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA 
 
 The characterization of primary central nervous system lymphoma (PCNSL) via noninvasive 
imaging modalities is essential for early diagnosis and differentiation from other brain lesions. 
Diffusion-weighted magnetic resonance imaging (DW-MRI), in which intensity of image contrast 
reflects diffusion of water molecules by Brownian motion, offers additional information beyond that 
obtained from conventional MRI. In this retrospective study from two institutions, quantitative region of 
interest (ROI) analysis was performed using parametric apparent diffusion coefficient (ADC) maps in 
immunocompetent patients with newly diagnosed PCNSL prior to corticosteroid use or other therapy. 
Mean ADC values and ratios were calculated for PCNSL lesions, peritumoral edema, and 
contralateral normal white matter. Quantitative DW-MRI analysis (n=12) revealed significant inter-
group variance between the mean ADC of lesion, peritumoral region, and normal white matter. Tukey 
post-hoc comparison of the three groups indicate that the mean ADC of the peritumoral region is 
significantly different (p<0.05) from mean ADC of the lesion and normal white matter, while 
differences between mean ADC of the lesion and normal white matter were not statistically 
significant. A comprehensive review of prior investigations reporting ADC values in evaluation of 
PCNSL was also conducted. We found that restricted diffusion is a consistent imaging finding in 
immunocompetent PCNSL patients and a reliable surrogate marker of tumor cellularity; however, the 
ranges of ADC values reported for PCNSL varied between studies and also overlapped with ADC 
ranges reported for other brain tumors. Given the observed variability in ADC values, it is essential to 
consider DW-MRI data as an adjunct diagnostic tool interpretable only in the context of clinical 
presentation and conventional MRI data. Further prospective investigation enrolling patients prior to 
corticosteroid therapy will be necessary to obtain standardized pre-treatment ADC values. 
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Primary central nervous system lymphoma (PCNSL) is an aggressive 
extranodal non-Hodgkin (NHL) lymphoma that targets brain, vitreous body and optic 
nerves, leptomeninges, and spinal cord. (1-2)  PCNSL accounts for approximately 
2.4% of all primary CNS neoplasms by most recent estimates. (3) The incidence of 
PCNSL increased approximately threefold in the 1980s and early 1990s, with the 
rate of increase levelling off since then. (4-5) Individuals with congenital or acquired 
immunodeficiency such as HIV or immunosuppressive therapy after an organ 
transplant are predisposed to developing PCNSL, and it is believed that the 
reduction in rate of increase of PCNSL incidence is at least partially attributable to 
the introduction of highly active antiretroviral therapy (HAART) in the mid-1990s. (5) 
Nevertheless, incidence continues rise in both immunocompetent and 
immuncompromised populations, across all age groups and in both men and 
women. (6)  
The clinical history of patients with PCNSL is variable. Most commonly, 
patients present with signs of a focal mass lesion, including evidence of increased 
intracranial pressure, seizures (more often in patients with AIDS), disturbances of 
vision, confusion, lethargy, memory loss, and neuropsychiatric manifestations. (7) 
Vague or unusual presenting complaints are also possible, e.g. a recent case report 
of fever of unknown origin as the sole presenting manifestation, (8) or 
panhypopituitarism and diabetes insipidus due to bilateral hypothalamic involvement. 
(9) A neurologic prodrome is sometimes seen up to years prior to diagnosis, which 
can include chronic vitritis (10) or multiple sclerosis. (11,12,13) Demyelinating 
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“sentinel” lesions that recede spontaneously up to months/years before the 
development of PCNSL have also been reported. (14-15) Whether these disorders 
reflect an early stage of malignancy heralding PCNSL or atypical polyclonal 
lymphoproliferations remains unclear. So-called “B” symptoms (fever, weight loss, 
night sweats) common in other forms of NHL are seldom seen except in the rare 
case of systemic dissemination. 
For patients who present with acute symptoms of brain tumor, non-contrast 
computed tomography (CT) of the head is the initial test of choice, primarily as a 
screening tool to rule out immediately life-threatening intracranial pathology such as 
a herniation or bleed. (16) However, due to the poor soft tissue contrast of head CT, 
this imaging modality is not effective at discriminating subtle non-enhancing 
parenchymal changes. (17) Given the additional ionizing radiation exposure and the 
risk of contrast-induced hypersensitivity, head CT is reserved for initial acute 
evaluation due to its wide availability, speed, and relatively low cost.  
For further evaluation of patients with suspected brain tumor, the most 
sensitive and specific diagnostic imaging modality is gadolinium contrast-enhanced 
magnetic resonance imaging (MRI). (2) Its advantages are numerous: superior 
anatomical detail, less risk of intolerance with gadolinium vs. iodinated contrast, no 
ionizing radiation, and flexible acquisition in multiple planes. The standard protocol 
includes contrast-enhanced T1 and fluid attenuated inversion recovery (FLAIR) 
sequences; T1 with contrast is well-suited for evaluating disruption of the blood-brain 
barrier with subsequent leakage of gadolinium, while FLAIR (a T2-weighted image in 
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which free water is attenuated) is excellent at identifying peritumoral edema and 
extent of tumor infiltration. (16,18)  
Using these conventional MRI sequences, PCNSL typically presents in 
immunocompetent patients as homogenously enhancing solitary or multiple lesions, 
often in a periventricular location with spread along white matter tracts producing 
mild edema or mass effect. (19,20,21) Lesions are hypointense or hyperintense on 
T1-weighted images and roughly 40% are hyperintense T2-weighted signal by 
recent estimates. (22) However, in immunocompromised individuals T2 
hyperintensity is more common, which has been show to correlate histologically with 
degree of intratumoral necrosis. (23) FLAIR sequence will demonstrate extensive 
perifocal edema with nonenhancing tumor area. In terms of distribution, a recent 
series of 100 immunocompetent PCNSL cases revealed lesions in cerebral 
hemisphere (38%), thalamus/basal ganglia (16%), corpus callosum (14%), 
periventricular region (12%), and cerebellum (9%). (24) Spinal cord or brainstem 
involvement, meningeal or ventricular enhancement, calcification and hemorrhage 
were uncommon.  
The pattern of enhancement in PCNSL is variable, particularly in HIV/AIDS 
patients or other immunocompromised individuals in which multiple lesions and rim 
enhancement surrounding zones of central necrosis are more common (19). This 
creates a diagnostic dilemma in distinguishing PCNSL from another common AIDS-
associated space-occupying lesion, CNS toxoplasmosis, which has a similar rim-
enhancing appearance on MRI. (25) Diagnosis is further complicated by the empiric 
use of corticosteroids in the patient population, which can significantly alter the 
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appearance of PCNSL lesions by reducing contrast enhancement and brain edema 
and altering cellular morphology through a direct lymphocytotoxic effect. (26) 
 Given these diagnostic challenges, there is great interest in utilizing other 
noninvasive imaging modalities and/or biomarkers in order to better characterize 
PCNSL and differentiate it from other tumors. One such modality is diffusion-
weighted MR imaging (DWI), in which intensity of image voxels reflects microscopic 
diffusion of water molecules in tissues by stochastic (Brownian) motion. (27) A brief 
technical review of DWI will now be presented to provide a theoretical framework for 
discussion of its clinical applications and rationale for use in PCNSL.  
Basic Principles of Molecular Diffusion and Diffusion-Weighted Imaging 
First described by Einstein in 1905, (28) the principle of Brownian motion 
states that molecules in a fluid medium diffuse randomly as a result of the thermal 
energy carried by those molecules. (27) Assuming a homogeneous medium of  “free 
water,” diffusion follows a three-dimensional Gaussian distribution with a variance !2 
= 2 * D * t where t = time allowed for diffusion and D = diffusion coefficient, which 
reflects size of molecules, temperature, and viscosity of a medium. (29) Biological 
tissues are far from homogeneous, however, and present obstacles to diffusion 
(cellular membranes, organelles, etc.) that result in anisotropic diffusion in a non-
Gaussian pattern, particularly as diffusion distance increases. Diffusion MRI 
provides insight into microscopic tissue structure – and perturbations in that 
structure caused by pathologic states – by non-invasively recording diffusion of 
water molecules in vivo.  
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In conventional MRI techniques, a homogenous magnetic field is applied to 
stimulate precession of water hydrogen nuclei (protons) around an axis parallel to 
the direction of the magnetic field. The key difference of DWI is that a “dephasing” 
pulse field sequence consisting of two symmetrical gradient pulses is applied to 
introduce variance in magnetic strength. As early as 1950, Hahn discovered that in 
the presence of a heterogeneous magnetic field, protons spin so as to reduce signal 
intensity. (30) Precession rate of protons varies proportionally to magnet strength, in 
the same way that the precession rate of a gyroscope depends on the force of 
gravity. (31) Applying a pulsed field gradient in DWI thus alters the rate of 
precession of protons and leads to phase dispersion of their transverse 
magnetizations (xy component of net magnetization vector), which results in signal 
loss. (32) A “rephasing” radiofrequency (RF) pulse identical in direction but opposite 
in magnitude is applied to refocus this dispersion in between the gradient pulses. 
However, spins that have moved along the gradient axis in the interval between the 
application of the first and second gradient pulses will not be reset to their initial 
state; rather, a phase shift will occur relative to the hydrogen protons of immobile 
water molecules. This manifests as signal loss because the overall vectorial sum of 
the spin phases in a dispersed state is less than if they were all precessing 
synchronously.  
The amount of signal loss can be predicted with the following equation 
originally described by Stejskal and Tanner in 1965:  
 




where S is signal after pulsed field gradient application; S0 is signal intensity prior to 
gradient application; " is a constant termed the gyromagnetic ratio, representing the 
ratio of a proton nuclear magnetic dipole moment to its angular momentum—when 
multiplied by the magnetic field strength in Tesla (T), this represents the rate of 
proton nuclear precession known as the Larmor frequency; (34) G and # are 
strength and duration of gradient pulse, respectively; $ is time between application 
of two pulses; D is the diffusion coefficient; and b-value is a summary “diffusion-
sensitizing factor” reflecting the overall strength of diffusion weighting. (33) A 
summary of the diffusion MR pulsed field gradient incorporated into a representative 
spin-echo sequence is provided in Figure 1. 
According to Stejskal and Tanner’s equation, four major variables can impact 
DWI signal intensity: time between application of the two gradients, strength and 
duration of gradient pulse applied, and the diffusion coefficient. It makes sense 
intuitively that signal intensity decreases as the amount of time between application 
of the two gradient pulses increases, because water molecules are allowed more 
time to diffuse; consequently, the phase refocusing pulse is less exact due to a 
larger displacement distribution of spins, which translates as signal attenuation. 
Signal intensity also varies proportionally with the strength and duration of the 
gradient pulse applied. These effects reflecting diffusion sensitization are 
summarized by the b-value. Finally, signal intensity varies according to the intrinsic 
rate of diffusion in tissues represented mathematically by the diffusion constant. 
Simply stated, faster diffusion results in larger phase shifts and greater signal loss. 




Diffusion weighting can be used with many different imaging sequences but 
echo planar imaging (EPI) is often utilized because acquisition is rapid (typically in a 
single acquisition period of 25-100 msec) (35) and macroscopic motion artifacts (e.g. 
“ghosting,” “blurring”) due to patient motion, breathing, or pulsatile blood flow are 
consequently minimized. (36) Motion is a particular issue for diffusion MRI because 
the microscopic motion of interest that induces phase shifts in spins can easily be 
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confounded by macroscopic motion of the type described above. This would not 
necessarily be an issue if all spins experienced the same approximate displacement, 
but because each sequence is repeated several times, the aberrant macroscopic 
motion pattern is present in some runs but not others, resulting in the “ghosting” 
artifact. As is often unfortunately the case, however, the solution to this problem 
introduces problems all its own— EPI itself is prone to artifacts such as chemical 
shift and eddy currents produced when gradient pulses are switched on and off, and 
the magnetic field gradient generates a current through the conducting surfaces of 
the MRI scanner. (36)  
 Another important caveat is that diffusion-weighted images do not provide the 
most accurate indicator of the diffusion coefficient. This is because visual contrast on 
DWI is not solely b-value dependent, but also reflective of other weighting 
mechanisms (e.g. T2 relaxation). (31) In fact, when b-value = 0, the image sequence 
is simply that of a T2-weighted sequence which only reflects diffusion weighting 
once a pulsed field gradient is applied. A classic example of a problem in 
interpretation stemming from this issue is “T2 shine through” in which a 
hyperintensity on DWI may reflect T2 weighting and cannot be differentiated from 
true diffusion restriction. (36) In order to characterize water diffusion free of similar 
confounders, it was proposed that the physical diffusion coefficient be replaced by a 
statistical parameter, the apparent diffusion coefficient (ADC). (37) To calculate 
ADC, b-values from at least two acquisitions (typically b=0 and b=1000 s/mm^2) are 
plotted logarithmically against signal intensity, and the slope (i.e, rate of signal 
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decay) is deemed the diffusion constant, which can be mapped pixel-by-pixel to 
create a parametric ADC image map (Figure 2).  
 As a statistical parameter, ADC depends not only on intrinsic physical 
diffusion properties but also on other technical features such as diffusion time and 
voxel size; additionally, the scaling from voxels (usually on the order of a few cubic 
millimeters) results in an averaging or smoothing effect (36-38). How, then, do 
scientists and clinicians rationalize the fact that different portions within a single 
voxel may have significantly different diffusion properties? The parameterization and 
averaging has been likened to the efforts of meteorologists to describe natural 
atmospheric processes on a scale much larger than the local physical forces being 
approximated, forces that technical limitations prevent us from accurately 
measuring, whether it be diffusion in tissue microarchitecture or the microphysics of 
thunderstorms. (38) The underlying assumption is that as long as one can make 
reliable and informed predictions based on the data, the parameter need not reflect 
the physical environment with complete accuracy in order to remain a useful clinical 
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Clinical Applications of Diffusion-Weighted Imaging  
In the clinical setting, DWI has proven most useful in distinguishing between 
cytotoxic and vasogenic edema in cerebral ischemia. (39, 40) In vasogenic edema, 
tight endothelial junctions comprising the blood-brain-barrier (BBB) are disrupted, 
resulting in variable signal intensity on DWI and higher ADC due to spread of protein 
and fluids into the extracellular space. (41) Conversely, restricted diffusion with DWI 
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hyperintensity and low ADC is observed in cytotoxic edema, reflecting a loss of 
extracellular fluid with commensurate swelling of intracellular compartments due to 
cellular retention of sodium and water from ATP depletion and consequent failure of 
the Na+/K + ATPase. (42,43) Cytotoxic edema is most characteristic of early acute 
ischemia, with changes in ADC occurring with minutes after onset, but can also be 
seen with various intoxications, encephalopathies, hypoglycemia, status epilepticus, 
or any other non-ischemic cause of deranged cellular metabolism. (44) Conversely, 
T2-weighted images will remain normal for several hours, eventually displaying an 
increase in intensity due to vasogenic edema. (45) ADC values in acute stroke reach 
their nadir by 24 hours and persist for 1-2 weeks, and although “cytotoxic edema” is 
repeatedly attributed as the explanation for persistent changes on DWI, (46) several 
researchers have suggested there are likely to be other mechanisms underlying 
ADC change that have not yet been elucidated. (47) Nevertheless, DWI has proven 
very sensitive (although some lacunar infarcts may not be detected) and reasonably 
specific in early detection of acute ischemic stroke during the crucial ‘window of 
opportunity’ for therapy. (48) 
In recent years, research into clinical applications of DWI has greatly 
expanded in an attempt to better characterize neurologic disorders other than acute 
stroke. (49) For example, movement disorders including Parkinson’s disease, 
progressive supranuclear palsy, and multiple system atrophy (50,51) have been 
studied with a ROI-based approach that readily differentiated some of these 
conditions on the basis of DWI findings. Diffusion MRI has also been employed in 
studying features of Alzheimer’s Disease (AD) and non AD-type dementias, (52) 
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early diagnosis of Creutzfeld-Jakob disease, (53) multiple sclerosis, (54) herpes 
encephalitis, (55) and epilepsy (including status epilepticus, interictal phases, and 
single seizures). (56) In addition, DWI has been used to differentiate arachnoid and 
epidermoid cyst (57) and subtypes of brain abscesses, including differentiation of 
pyogenic abscess from necrotic tumor. (58) This list is far from comprehensive, as 
an explosion of clinical literature utilizing this technique has occurred in a relatively 
short period of time, reflecting the tremendous potential of diffusion imaging for use 
in the clinical setting. 
The literature concerning DWI in diagnostic evaluation of patients with brain 
tumors has increased particularly rapidly; several recent studies have attempted to 
correlate ADC with cellularity or grade of various tumors, assess infiltration into 
peritumoral edema, or differentiate among tumors that can otherwise appear similar 
using conventional MR techniques (e.g. PCNSL, glioblastoma multiforme, anaplastic 
astrocytoma, metastases). (59) Many early studies, however, were not encouraging; 
for example, a study aimed at distinguishing between tumor tissue and peritumoral 
edema in gliomas found no ability to differentiate on the basis of absolute ADC 
values or ADC ratios. (60) Another study found that ADC was helpful in grading of 
malignant brain tumors in a sample of 33 low-grade (23 astrocytomas, 10 
oligodendogliomas) and 40 high-grade (25 metastases, 15 high-grade astrocytomas) 
neoplasms, but was unhelpful in differentiation among them. (61) In a 2001 study 
examining 56 patients with the three most common types of intracranial neoplasms 
(gliomas, metastases, and meningiomas), too much variation existed within each 
group to reliably differentiate among them on the basis of either DWI or ADC maps. 
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(62) Furthermore, the authors were unable to successfully use either DWI or ADC to 
assess tumor infiltration or differentiate infiltration from perifocal edema, which 
contradicted a previous report. (63) Another 2001 study found considerable overlap 
in ADC values and could not separate tumor from surrounding edema in a small 
sample of patients with high-grade cerebral glioma. (64) A third 2001 study found no 
advantage of DWI in evaluating tumor extension in a sample of patients with 
gliomas, metastases, meningioma, and abscess. (65) 
This led a member of the editorial board of the neuroradiology journal in 
which several of the above articles were published to state in 2001 that “the bloom 
[is] off the rose” with respect to the use of DWI in evaluation of brain tumors: “There 
is a natural history for new diagnostic tests. The initial results are amazing, the 
praise overwhelming. The test is viewed as having almost magical qualities. After a 
while, reality sets in. The initial enthusiasm wanes as experience accumulates. This 
is where we are now with diffusion-weighted imaging.” (66) Yet, the author 
concluded that DWI was nevertheless a potentially valuable tool, particularly when 
studies utilized a quantitative analysis of specified ADC regions of interest, as a 
more sensitive way of revealing significant abnormalities that may not be readily 
apparent simply by looking at a diffusion-weighted image or ADC map.   
  A small number of studies have begun to characterize DWI findings in 
patients with PCNSL, (67,68) attempt to differentiate between PCNSL and other 
tumors on the basis of DWI, (69,70,71,72,73,74) and even utilize ADC as a predictor 
of clinical outcome and response to therapy. (75) Yet, the body of literature available 
for comparison of findings in PCSNL remains relatively small, as does the sample 
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size in individual studies. Additionally, studies utilizing DWI in the characterization of 
PCSNL continue to appear with findings that contradict prior reports; as recent as 
2009, Server et al. found no significant difference between malignant gliomas and 
PCSNL on the basis of DWI. (76) Is the “bloom off the rose” in the case of diffusion-
weighted imaging in PCNSL, or will ADC be established in time as a surrogate 
marker of cellularity to characterize and differentiate among tumors, and perhaps 
even predict therapeutic response? Given the need for additional clarity in the 
relatively meager and sometimes conflicting literature, and as the incidence of 
PCNSL continues to rise in the population, we conducted a retrospective study 
utilizing a comprehensive neuroimaging protocol including DWI and quantitative 
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Statement of Purpose: 
  The purpose of this investigation was to identify and characterize the earliest 
DW-MRI findings in patients with PCNSL prior to corticosteroid use or other therapy. 
Quantitative region of interest analysis was performed using parametric ADC maps. 
ADC values derived from this study were then compared to measurements from 
other studies via a comprehensive review of prior investigations utilizing DWI in the 
evaluation of PCNSL. The hypothesis was that restricted diffusion is a reliable 
marker of increased tumor cellularity in PCNSL, and that ADC values may be useful 
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Three databases were accessed to gather subjects: the Connecticut Cancer 
Registry, the Yale School of Medicine (New Haven, CT) Brain Tumor Center 
database, and the Massachusetts General Hospital (Boston, MA) Brain Tumor 
Center database. The dates evaluated were between January 1982 and July 2007 
for the Connecticut and Yale databases, and between January 2000 and June 2007 
for the MGH database. Patients with PCNSL were included only if they had a 
histopathologically confirmed diagnosis. Exclusion criteria included congenital or 
acquired immunodeficiency (e.g., HIV), lymphoma without cerebral involvement 
(e.g., primary intraocular lymphoma), or patients where insufficient clinical 
information was available to ascertain appropriateness for inclusion (e.g., missing 
histopathology report or imaging data at diagnosis).  
137 immunocompetent patients with PCNSL were initially identified, including 
45 cases from Yale and 95 cases from MGH. Of these, 56 cases were excluded due 
to insufficient data or lack of access to imaging performed at the time of initial 
diagnosis. In addition, nine cases were primary intraocular lymphoma without CNS 
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spread, leaving a total of 72 cases meeting entry criteria. Of these, sixteen cases 
with DWI data and ADC maps available in PACS for region of interest analysis were 
identified. Four were excluded due to insufficient data, leaving a final cohort of 12 
cases for quantitative DW-MRI analysis. The study cohort includes 9 men and 3 
women with a median age of 48.5 years (range 14-73), including one pediatric case 
aged 14 at time of diagnosis. 
MR Imaging 
This study was retrospective in nature, so MRI protocols and timing are not 
standardized among patients. A 1.5T MR Imaging unit was used at both Yale-New 
Haven Hospital and MGH. T1-weighted spin-echo images were obtained in axial, 
coronal, and sagittal planes with the following parameters: repetition time [TR]=600 
ms; echo time [TE]=20 ms; number of excitations=1, and long-TR dual-echo axial 
sequences (2500/30.9/1). Other imaging parameters include: field of view=21 cm, 
256x192 matrix slice thickness 5 mm with spacing of 0-2 mm. T1-weighted axial 
images were obtained before and after intravenous administration of gadopentate 
dimeglumine contrast medium (0.1 mmol/kg). ADC maps were generated based on 
diffusion-weighted echo planar sequences. Six high b-value images (1000 mm%/s) 
and one low b-value images (3 mm%/s) were acquired for each of 23 axial slices. The 
following parameters were used: TR=10 s, TE=104 ms, diffusion encoding 
gradients=45 ms, 128x128 matrix, field of view, 24.5 mm slice thickness, 1mm 
spacing, one signal average.  
 




Postprocessing of apparent diffusion coefficient (ADC) maps and values 
occurred on a Siemens workstation (Siemens Medical Solutions, USA). DWI images 
and ADC maps were aligned with contrast-enhanced T1-weighted and FLAIR 
images corresponding to the same section level. Patients were retrieved from PACS 
using a combination of date and medical record number, and all images retrieved 
were rendered anonymous and free of any patient identifiers. ROIs were drawn from 
the solid enhancing region of tumor, peritumoral edema, and contralateral normal-
appearing white matter (Figure 1) using a circular pixel lens tool available in the 
workstation. All ROIs drawn were approved by a neuroradiologist blinded to all 
information other than diagnosis (R.K.F.). ROI areas ranged between 0.47-0.78 cm2 
and were drawn to avoid necrotic or hemorrhagic areas.  Values for ADC mean, 
minimum, and standard deviation were calculated. Ratios (ADC of tumor focus to 
ADC of peritumoral region; ADC of tumor focus to ADC of contralateral normal white 
matter) were also calculated. Inter-group variance in mean ADC values between 
ROI groups was assessed using one-way Analysis of Variance (ANOVA). All ADC 
values are reported as 100 x 10^-6 mm2/s. Pairwise post-hoc comparison of mean 
ADC values between groups was performed using Tukey’s HSD test at the p<0.01 
level of significance.  
Literature selection 
 Prior studies utilizing DWI in the study of PCNSL were chosen by searching 
MEDLINE, Web of Science, and Google Scholar for articles listed between 1992 
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(when DWI was first used in the early diagnosis of cerebral ischemia) and 2010. 
Relevant search terms were used, including any combination of “diffusion-weighted 
imaging,” “diffusion imaging,” “DWI,” “DW-MRI,” or “diffusion MR imaging” with 
“primary CNS lymphoma,” “central nervous system lymphoma,” “primary lymphoma 
of the central nervous system,” “brain lymphomas,” “cerebral lymphoma,” or 
“PCNSL”. After scanning titles and abstracts, relevant full articles were reviewed to 
select those reporting original research using quantitative ADC/DWI measurements. 
In addition to these measurements, the following information was retrieved for each 
study: authors, year of publication, number of cases, average age of patients, 
stratification of patient groups, and methods of ROI drawing and ADC calculation.   
 
Figure 1: Apparent diffusion coefficient (ADC) map (a) and axial gadolinium 
contrast-enhanced T1-weighted MR image (b) at same level in case of primary 
CNS lymphoma. ROIs are placed centrally in the core of the lesion, in the 
adjacent peritumoral edema, and in contralateral normal white matter. 
 
(a)      (b) 
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Results       
ROI analysis was performed for cases with DWI and ADC maps available 
(n=12), an example of which is illustrated in Figure 2. The mean ADC and range of 
the enhancing portion of PCNSL lesions was 888 +/- 137 x10-6 and 609-1065 x10^-6 
mm2/s, respectively. The minimum ADC and range of the enhancing portion of lesion 
was 704 +/-185 x10-6 and 326-947 x10-6 mm2/s, respectively. The mean ADC and 
range of the peritumoral region was 1429 +/- 272 x10-6 and 1162-1934 x10-6 mm2/s, 
while the mean ADC and range of contralateral normal-appearing white matter was 
878 +/- 146 x10-6 and 578-1083 x10-6 mm2/s, respectively. The ADC ratio of the 
enhancing portion of the lesion to surrounding perifocal edema was 0.64 +/-0.13, 
while the ratio of the enhancing portion of lesion to contralateral normal-appearing 
white matter was 1.12 +/-0.07.  
 One-way Analysis of Variance (ANOVA) revealed significant inter-group 
variance between the mean ADC of lymphomas, peritumoral regions, and 
contralateral normal white matter (F (2,33)=31.438, p<0.001). Tukey post-hoc 
comparison of the three groups indicate that the mean ADC of the peritumoral lesion 
is significantly different from the mean ADC of the lesion and normal white matter. 
However, differences between mean ADC of lesion and normal white matter were 
not statistically significant at p<0.01. 
 Our literature search for prior studies of DWI in PCNSL revealed 13 articles 
that met eligibility criteria for comparison, describing a total of 133 separate patients 
with lymphomas for which DWI/ADC quantitative measurements were recorded 
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(Table 1). Ten out of thirteen reported ADC values of lymphoma lesions as means, 
four studies reported ADC minimums, and two studies reported ADC medians. One 
study provided data on 25th percentile ADC values and another reported ADC 
maximums. Two out of thirteen did not provide complete information regarding 
standard deviation of reported values, and three out of thirteen did not provide a 
range of values. In two studies, range could only be approximated based on boxplot 
data. Two out of thirteen reported ADC measurements from perilesional edema or 
contralateral normal white matter; in one additional study, the mean ADC value for 
normal white matter was approximated from the reported ADC ratio of lesion to 
contralateral normal white matter. This ratio was reported in five out of thirteen 
studies. However, only one study prior to ours reported a ratio of lesion to 
surrounding peritumoral edema. Most studies reported data from immunocompetent 
patients or did not specify patient immune status; however, one study (Camacho et 
al.) was strictly limited to AIDS patients, another (Kitis et al.) stratified ADC values 
into immunocompetent and immunocompromised patient groups, and a third 
(Zacharia et al.) included both immunocompetent and immunocompromised 
individuals but stratified ADC reporting based on pattern of enhancement rather than 
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Table 1: Comparison of Diffusion-Weighted Imaging Findings in PCNSL.  
All ADC 
values 
reported      
(x10^-6 
mm2/s). 
N  ADClesion   Range ADC perilesion     ADC normal  Ratio  ADC 
lesion/normal        
Ratio ADC 
lesion/perilesion  






1.02+/-0.07 0.64+/-0.13  
Guo et al., 2002 11 870+/-270 
(mean) 
n/a n/a 750 +/- 40 
(mean) 
1.15+/-0.33 n/a 
Camacho et al., 
2003              
(AIDS patients) 
 4 930(SD n/a) 
(mean) 
670-1200 n/a n/a 1.14+/-0.25 n/a 




6      
2 
540+/-100 
(min)                    
550+/-120 
(min)                           
n/a 
350-670 
n/a           
n/a 
n/a n/a n/a n/a 
Yamasaki et al., 
2005 
 8 725+/-192 
(mean) 
504-1067 n/a  n/a n/a n/a 
Calli et al., 2006  8 510 +/- 90 
(min) 
~400-650 n/a n/a n/a n/a 
Reiche et al., 
2007   




n/a n/a n/a 
Al-Okaili et al., 
2007 
12 860+/- 220 
(mean)                    
990        
(median) 
370-1100 n/a n/a n/a n/a 
Toh et al., 2008 10 630+/-155 
(mean) 
371-806 n/a 752 +/-86 
(mean) 
0.83+/-0.14 n/a 
Akter et al., 2008      
DWI- 











840+/-110   
              
960+-210 
(mean) 
n/a n/a n/a n/a n/a 
Zacharia et al., 
2008 
Homo/Heterogeneous  
Ring enhancing                                                              
-    (Lesion Periphery)                   
20  
(15)   
(5)                     
 
650+/- 43                                                               
720+/-41         
 
570-720                      
650-800                      
n/a n/a n/a n/a 
   
 
23 
-    (Lesion Center)              
Post-Treatment  
        
(7) 
1140+/-20        
n/a            
(mean) 
1060-1210      
860-1140                




~500-900 n/a n/a 0.93+/-0.19 n/a 
Server et al., 
2009 
5 732+/-170 











(mean)               
1.03+/-0.26 
(min)            
0.46+/-0.08 
(mean)     
0.43+/-0.08 
(min)    
Barajas et al., 
2010  
                          
Response 
Groups                 
-  Primary 
Refractory              
 
-  Clinical 
Response  
18               
                                                       
 
   
(7)           
 
  
(11)   
830(SD n/a) 
(mean)           
377(SD n/a) 
(min)               
                  
757+/-96 
(mean)                        
244+/-84 
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Figure 2:  Typical DWI findings in PCNSL. Diffusion-weighted imaging (A) 
shows hyperintensity corresponding to a right occipital mass, while ADC map 
(B) shows low signal consistent with restricted diffusion. Gadolinium contrast-
enhanced T1-weighted imaging shows strong homogeneous enhancement in 
the mass (C), which can be seen on FLAIR (D) to invade the splenium of 
corpus callosum and right lateral ventricle.  
 
 
A             B 
 
C            D 
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Discussion   
A small number of studies have attempted to characterize DWI findings in 
PCNSL, (65-68, 77) differentiate between PCNSL and similarly appearing tumors, 
(69-74) or predict response to therapy and clinical outcome. (75) DWI is thought to 
provide information about tumor cellularity or grade because water diffusion 
correlates highly with the ratio of extracellular to intracellular space, (33,41) with 
greater diffusion expected in an extracellular medium. (37) A highly cellular tumor 
such as PCNSL serves as a significant barrier to water diffusion by decreasing the 
volume and increasing the tortuosity of the extracellular space, which is (in theory) 
reflected as a relative decrease in ADC value and increased signal on DWI 
compared to less cellular tumors.  
Although several groups have provided data in support of restricted diffusion 
as a consistent finding on DWI in PCNSL, to date there has not been a 
comprehensive review of quantitative methods and measurements among 
investigators. We presented the ADC values derived in our study with a summary of 
findings from prior work in Table 1. The earliest quantitative study using ADC values 
in PCNSL was a 2002 retrospective series of 19 brain lymphomas in 11 patients by 
Guo et al., which used ADC ratios of tumor to normal-appearing regions in a small 
cohort of patients with either lymphoma or astrocytoma. (69) Sixteen of nineteen 
lesions appeared hyperintense on DWI and iso- to mildly hypointense on ADC 
signal; additionally, an inverse correlation between diffusion and cellularity was 
reported based on calculation of nuclear-to-cytoplasmic (N/C) ratios in histologic 
samples. However, the correlation between ADC values and N/C ratios was 
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relatively modest (r=-0.46). A later study confirmed an inverse correlation between 
mean ADC and cellular density of similar magnitude (r=-0.54). (75) This suggests 
that factors other than tumor cellularity are at play in determining ADC values, which 
may include degenerative changes such as hemorrhage or abscess and local effects 
due to expression patterns of hydrophilic components of the extracellular matrix. (78) 
PCNSL in immunocompetent patients is typically a non-necrotic, homogeneous-
appearing tumor lacking these confounding degenerative changes; thus, it is 
believed that DWI represents a potentially useful and specific diagnostic tool for this 
disease.  
 In a similar series of 16 patients with PCNSL, thirteen (80%) were 
hyperintense or partially hyperintense on DWI, which corresponded to lower overall 
mean ADC values than isointense lesions; however, significant overlap existed 
between all three groups. (79) Zacharia et al. studied 20 patients comprising both 
immunocompetent and immunocompromised as well as pre- and post- treatment 
cases, finding areas of restricted diffusion in 90% (18/20) of pretreatment scans. (67) 
The ADC range was higher with significant variability in both post-treatment and 
immunocompromised individuals, presumably reflecting low cellularity as a 
consequence of increased necrosis and partial volume effect due to decreased 
lesion size. Another issue was highlighted in Reiche et al.’s DWI study of four 
PCNSL cases, one of which displayed an absent enhancement pattern that delayed 
time to diagnosis and biopsy. (68) This pattern of enhancement is a rare but known 
(80) presentation of PCNSL and underscores the potential of DWI—which showed 
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lesions in this case to be hyperintense with low ADC suggestive of a hypercellular 
neoplasm—to provide clues in difficult diagnostic situations.          
A number of investigators have attempted to use DWI to distinguish PCNSL 
from other lesions that appear similar on conventional MRI (e.g. glioblastoma 
multiforme, anaplastic astrocytoma, some highly cellular metastases). One such 
study used minimum ADC values to differentiate low-grade gliomas from high-grade 
gliomas, metastases, and lymphomas, observing consistently low ADC values for 
the latter; however, this difference did not achieve statistical significance and the 
range of lymphoma ADC values overlapped with those of high-grade gliomas. (81) 
Server et al. also found no significant difference between malignant gliomas and 
PCSNL with DWI. (76) A third group found no difference on the basis of either mean 
ADC of enhancing tumor or ADC ratio of tumor to uninvolved white matter between 
lymphoma and glioblastoma in a study restricted to invasion of the corpus callosum. 
(72) However, echoing an earlier report by Guo et al., they did find a significant 
difference on the basis of ADC values between lymphomas and astrocytomas. In 
contrast to the prior studies, a report by Calli et al found a significant difference 
between lymphomas and both GBMs and AAs on the basis of minimum ADC values. 
(73) Similarly, Toh et al. and Yamasaki et al. found a significant difference between 
PCNSL and GBM based on ADCs. (70-71) However, there was considerable 
overlap in the range of values between groups in all three of these studies. This 
conflicting evidence highlights the lack of clarity in the literature and the importance 
of interpreting potentially variable ADCs in the context of a full clinical and MR 
imaging evaluation. 
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DW-MRI has also been used to evaluate select populations in which the 
differential diagnosis of brain masses can be particularly challenging, such as 
patients with AIDS. In these individuals, toxoplasmosis and PCNSL are the two most 
common etiologies. The characteristic rim-enhancement and profound vasogenic 
edema of infectious abscess is often difficult to distinguish from tumor in 
immunocompromised hosts. Camacho et al. used ADC values to differentiate 
PCNSL from toxoplasmosis in patients with AIDS, and although there was a 
statistically significant difference between the two groups, there was again 
considerable overlap in the range of ADC values. (82)  
Overall, there is a demonstrated trend of either negative results or reports of 
statistical significance belied by significant overlap between ADC values in the 
literature regarding use of DWI in differential diagnosis of PCNSL. This is consistent 
with several studies that have reported negative results attempting to use DWI or 
ADC maps to differentiate between various tumors not including PCNSL, or between 
tumor tissue and surrounding edema. (4,60-64) The range of values that we derived 
with a patient population and methods similar to prior reports also overlap 
significantly with reported range of ADCs for other tumors. Even for studies strictly 
limited to characterization of PCNSL, there is substantial variation in the range of 
ADC values reported. Among all studies, values ranged from 371-1200 x 10-6 mm2/s 
for the solid enhancing portion of a PCNSL lesion, and mean values ranged from 
650 – 930 x 10-6 mm2/s (Table 1). There is also a lack of consensus regarding which 
DWI metrics are most informative—investigators have reported ADC values in terms 
of means, medians, minimums, 25th percentiles, ratios, values for 
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homogeneously/heterogeneously enhancing vs. ring-enhancing portions of lesions, 
values for individual lesions vs. averages of regions from several lesions, and so 
forth. While there is intrinsic appeal to a DWI region of interest method where one 
can choose locations based on an a priori hypothesis about the relationship between 
tumor cellularity and ADC, there are other complex underlying pathological 
processes that influence the value obtained, thus rendering conclusions drawn from 
these widely varying and overlapping ADC ranges tenuous. Future studies 
comparing groups of tumors should establish firm “threshold” levels above or below 
which lesions can be differentiated with near-100% accuracy, rather than report a 
statistically significant difference between two overlapping ranges of values that are 
of little clinical benefit out of context. 
In addition to variance in how investigators choose to report ADC values and 
heterogeneity of PCNSL appearance and presentation, several other limitations of 
our study and the studies summarized in Table 1 account for the discrepant 
evidence in the literature. Many conclusions are based on a very small sample size 
(as few as 4 lesions), or with significant error in values reported (in the Guo et al. 
series, the standard deviation of the mean ADC for PCNSL lesions was 31% of the 
estimate itself). Variability is also introduced by using less than six b values in 
generation of an ADC map, and many of these studies used such a technique 
(although studies have shown that the error used by this method is small). (83) The 
sampling method is also a significant potential source of confounding. This includes 
error inherent to the subjective process of manually positioning regions relative to 
affected anatomical structures, difference of opinion among investigators regarding 
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whether areas of degeneration or necrosis or vascular territories should be included 
or excluded from regions of interest, (84) “normal-appearing” tissue on MR imaging 
actually representing underlying pathology and inappropriately being used as a 
tissue reference, and errors inherent to faulty software co-registration of images. 
Owing to the retrospective nature of these studies, some relevant images and 
clinical information or cases may have been missed. Patients exposed to 
corticosteroids or other conditions that could have altered the appearance of images 
used in analysis may have also been included inappropriately. Large-scale 
prospective studies in the future with strictly defined criteria for pre-treatment ADC 
determination should serve to address some of these issues. 
One other issue of note highlighted by our data is the lack of difference 
between mean ADC of the enhancing portion of PCNSL lesions and ADC of 
contralateral normal white matter. Less than half of prior studies measuring ADC 
values for PCNSL reported ratios normalized against normal white matter (Table 1). 
Although our absolute value for ADC of contralateral normal tissue is the highest 
among the studies that have reported these values, our ratio of ADC (lesion/normal) 
is in line with prior estimates, which have ranged from 0.83 to 1.15 with a standard 
deviation between 0.07 and 0.33 (Table 1). That these estimates typically include a 
possible ratio of 1 suggests little difference between the ADC of an enhancing 
PCNSL lesion and uninvolved normal white matter, which is surprising given the 
inverse relationship between cellularity and diffusion emphasized in the literature 
and the dramatically restricted diffusion relative to normal tissue one might expect in 
a highly cellular environment. This suggests that ADC measurements are not as 
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highly correlated with cellularity as imagined, and subject to other biophysical forces 
that remain poorly understood. One possibility may be related to the pathologic and 
histologic features of PCNSL, which are remarkable in that neoplastic cells tend to 
congregate in sheets along vascular channels. (85) It has been theorized that the 
mechanism of PCNSL spread is through enlarged perivascular (Virchow-Robin) 
spaces with infiltration of vessel walls. (86) This phenomenon may also predispose 
to partial volume effects with entrapped interstitial fluid in perivascular regions or 
vasogenic edema within lesions that could affect ADC values obtained. Additionally, 
while the absolute ADC value may not be helpful in delineating between normal 
white matter and PCNSL lesions, the ratio of lesion to perifocal edema highlighted a 
consistent and significant difference in our series. Our values are consistent with the 
one other study that reported this ratio (Table 1). Further research will be necessary 
to determine if the values we obtained for this ratio are reasonably specific for 
PCNSL.  
 Where does the future lie with regard to use of DWI in clinical evaluation of 
PCNSL? Current research is aimed at investigating its use in predicting clinical 
response and therapeutic outcome. In the past, DWI has been used to distinguish 
tumor recurrence from radiation-induced necrosis (87-88) or postoperative changes 
(89) and detect early response to therapy in brain tumors, (90-91) although 
conflicting studies have shown both increased (92) and decreased (93) ADC in 
response to treatment. Functional diffusion maps, in which voxel-by-voxel changes 
in ADC measurements are tracked through serial DWI, have also been shown to 
track tumor growth in gliomatosis cerebri (94) and predict treatment response in a 
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variety of tumors (not including PCNSL). (95-96) Barajas et al. tested the hypothesis 
that tumor cellular density in PCNSL as reflected by pre-treatment ADC values 
within contrast-enhancing regions of tumor could be used to predict clinical outcome. 
(75) Patients with 25th percentile ADC values <692 and minimum ADC values <384 
x 10-6 mm2/s predicted disease refractoriness as measured by shorter progression-
free and overall survival, while those above those thresholds had a reduction in post-
treatment ADC values and improved survival. (11) The authors state that the 
reduction in ADC values in the “high ADC” group might be due to reduced 
extracellular diffusion secondary to cellular swelling as a consequence of 
responsiveness to chemotherapy. However, the distance between treatment 
initiation and post-treatment imaging (up to several months) argues against this 
hypothesis. Regardless, the evidence that ADC is able to serve as a surrogate 
marker for therapeutic response is encouraging, and interest in post-treatment 
surveillance imaging biomarkers should remain high as chemotherapeutic and 
radiation therapy options advance and improve outcomes. 
The future of PCNSL imaging research lies also in the use of more 
sophisticated techniques. For example, diffusion is frequently anisotropic in the brain 
while “basic” DWI only measures diffusion speed along one direction. By varying the 
orientation of the MRI diffusion gradient along orthogonal directional axes, 
differences in diffusion and image contrast can be observed. (97) This technique, 
known as diffusion tensor imaging (DTI), is increasingly being used in the evaluation 
and differential diagnosis of PCNSL with promising initial findings; for example, 
fractional anisotropy (FA, an index of diffusion anisotropy that reflects the 
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microarchitecture of CNS white matter fibers) was significantly lower in PCNSL vs. 
GBM. (71, 98) Given that the directionality data in DTI could theoretically be applied 
to provide structural information regarding unique features of localization/infiltration 
of PCNSL lesions relative to white matter tracts, and that FA has been correlated 
strongly with cellularity, (99) it is likely that the body of literature studying not only 
DWI but also DTI in the evaluation of PCNSL will continue to expand.  
Taken together, our results support restricted diffusion as a consistent DWI 
finding in PCNSL, particularly as compared to peritumoral edema. This view is in 
accord with prior studies that have demonstrated an inverse correlation between 
ADC and cellularity of lesions. However, the reported strength of this relationship is 
modest, presumably due to other factors affecting ADC measurements that, in 
addition to methodological differences and other limitations of prior studies, account 
for the variance of values reported in the literature. There is currently insufficient 
evidence to advocate the use of ADC values as a definitive basis for differential 
diagnosis of intraaxial brain masses, as the ranges of ADC values reported for 
lymphoma frequently overlap with those of other tumors. However, in difficult 
diagnostic situations where clinical information and conventional MR imaging data is 
insufficient to render a diagnosis, use of DW-MRI may be helpful as an adjunct to 
point the clinician in the right direction, as in the example of a rare non-enhancing 
lymphoma lesion displaying restricted diffusion with a low ADC. Additionally, imaging 
strategies that incorporate multiple techniques may represent a path forward; for 
example, a recent study combined conventional MR imaging, perfusion MR imaging, 
and proton MR spectroscopy to differentiate high-grade neoplasms and lymphoma 
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from low-grade neoplasms and noncancerous lesions with an accuracy and 
sensitivity of 85% and 84%. (74) Ultimately, there remains no substitute for clinical 
judgment. Caution must be urged against overreliance upon quantitative 
measurements when arriving at a final diagnosis, and such data should always be 






















                                            
1 Hochberg, F., Baehring, J., & Hochberg, E. (2007). Primary CNS lymphoma. 
Nature Clinical Practice Neurology , 3 (1): 24-35. 
 
2 Gerstner, R., & Batchelor, T. (2010). Primary central nervous system lymphoma. 
Arch Neurol, 67 (3): 291-7. 
 
3 Central Brain Tumor Registry of the United States (2010). Statistical Report: 
Primary Brain Tumors in the United States 2004-2006. 
[http://www.cbtrus.org/reports] 
4 Hochberg, F., & Miller, D. (1988). Primary central nervous system lymphoma. 
Journal of Neurosurgery, 68 (6): 835-53. 
 
5 Diamond, C., Taylor, T.H., Im, T., Miradi, M., Wallace, M., & Anton-Culver, H. 
(2006). Highly active antiretroviral therapy is associated with improved survival 
among patients with AIDS-related primary central nervous system non-Hodgkin’s 
lymphoma. Curr HIV Res, 4: 375-8. 
 
6 Olson, J., Janney, C., Rao, R., Cerhan, J., Kurtin, P., Schiff, D., et al. (2002). The 
continuing increase in the incidence of primary central nervous system non-Hodgkin 
lymphoma: a surveillance, epidemiology, and end results analysis. Cancer, 95 (7): 
1504-10. 
 
7Bataille, B., Delwail, V., Menet, E., et al. (2000). Primary intracerebral malignant 
lymphoma: report of 248 cases. Journal of Neurosurgery, 92 (2): 261-66.   
 
8 Salih, B.S., Saeed, A.B., Alzahrani, M., Al Qahtani, M., Haider, A., Palker, V. 
(2009). Primary CNS lymphoma presenting as fever of unknown origin. J 
Neurooncol, 93 (3): 401-4. 
 
9 Layden, B.T., Dubner, S., Toft, D.J., Kopp, P., Grimm, S., & Molitch, M.E. (2009). 
Primary CNS lymphoma with bilateral symmetric hypothalamic lesions presenting 
with panhypopituitarism and diabetes insipidus. Pituitary [Epub ahead of print.] 
 
10 Intraocular-central nervous system lymphoma: clinical features, diagnosis, and 
outcomes (2000). Ocul Immunol Inflamm, 8 (4): 243-50. 
 
11Brecher, K., Hochberg, F.H., Louis, D.N., de la Monte, S., & Risking, P. (1998). 
Case report of unusual leukoencephalopathy preceding primary CNS lymphoma. J 
Neurol Neurosurg Psychiatr, 65 (6): 917-20.  
 
12Yang, J-H, & Wu, S-L. (2007). Multiple sclerosis preceding CNS lymphoma: a case 
report. Acta Neurol Taiwan, 16 (2): 92-7. 
  
   
 
36 
                                                                                                                                       
13Burgetova, A., Seidl, Z., Vaneckova, M., & Jakoubkova, M. (2008). Concurrent 
occurrence of multiple sclerosis and primary CNS lymphoma: a case report. Neuro 
Endocrinol Lett, 29 (6): 867-70. 
 
14Alderson, L., Fetell, M.R., Sisti, M., Hochberg, F., Cohen, M., Louis, D.N. (1996). 
Sentinel lesions of primary CNS lymphoma. J Neurol Neurosurg Psychiatr, 60 (1): 
102-5.  
 
15Ng, S., Butzkueven, H., Kalnins, R., & Rowe, C. (2007). Prolonged interval 
between sentinel pseudotumoral demyelination and development of primary CNS 
lymphoma. J Clin Neurosci, 14 (11): 1126-9.  
 
16 Cha, S. (2009). Neuroimaging in neuro-oncology. Neurotherapeutics, 6 (3): 465-
77. 
 
17 Ricci, P.E. (1999). Imaging of adult brain tumors. Neuroimaging Clin N Am, 9: 
651-69. 
 
18 Kates, R., Atkinson, D., Brant-Zawadzki, M. (1996). Fluid-attenuated inversion 
recovery (FLAIR): clinical prospectus of current and future applications. Top Magn 
Reson Imaging, 8: 389-96. 
 
19Lanfermann, H., Heindel, W., Schaper, J., Schroder, R., Hansmann, M.L., Lehrke, 
R., Ernestus, I., & Lackner, K. (1997). CT and MR imaging in primary cerebral non-
Hodgkin's lymphoma. Acta Radiol, 38 (2): 259-67. 
 
20Roman-Goldstein, S.M., Goldman, D.L., Howieson, J., Belkin, R., & Neuwelt, EA. 
(1992). MR of primary CNS lymphoma in immunologically normal patients. AJNR 
Am J Neuroradiol, 13 (4): 1207-13. 
 
21Bühring U., Herrlinger, U., Krings, T., Thiex, R., Weller, M. & Kuker, W. (2001). 
MRI features of primary central nervous system lymphomas at presentation. 
Neurology, 57 (3): 393-6. 
 
22 Coulon, A., Lafitte, F., Hoang-Xuan, K., Martin-Duverneuil, N., Mokhtari, K., 
Blustajn, J., Chiras, J. (2002). Radiographic findings in 37 cases of primary CNS 
lymphoma in immunocompetent patients. Eur Radiol, 12 (2): 329-40. 
 
23Johnson, B.A., Fram, E.K., Johnson, P.C., Jacobowitz, R. (1997). The variable MR 
appearance of primary lymphoma of the central nervous system: comparison with 
histopathologic features. AJNR Am J Neuroradiol, 18 (3): 563-72. 
 
24 Kuker, W., Nagele, T., Korfel, A., et al. (2005). Primary central nervous system 
lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol, 72 
(2): 169-177.  
   
 
37 
                                                                                                                                       
 
25 Berger, J.R. (2003). Mass lesions of the brain in AIDS: the dilemmas of 
distinguishing toxoplasmosis from primary CNS lymphoma (2003). AJNR Am J 
Neuroradiol, 24 (4): 554-5. 
 
26 Tan, B.R., & Bartlett, N.L. (2000). Treatment advances in non-Hodgkin’s 
lymphoma. Expert Opinion on Pharmacotherapy, 1 (3): 451-65. 
 
27 Thomsen, C., Henriksen, O., & Ring, P. (1987). In vivo measurement of water self 
diffusion in the human brain by magnetic resonance. Acta Radiol, 28: 353-61. 
 
28 Einstein, A. Investigations on the theory of the Brownian movement. New York, 
NY: Dover, 1956. 
 
29 Hagmann, P., Jonasson, L., Maeder, P., Thiran, J.-P., Wedeen, V.J., & Meuli, R. 
(2006). Understanding diffusion MR imaging techniques: from scalar diffusion-
weighted imaging to diffusion tensor imaging and beyond. RadioGraphics, 26: S205-
S223. 
 
30 Hahn, E. (1950). Spin echoes. Phys Rev, 80; 580-94. 
 
31 Mori, S., & Barker, P.B. (1999). Diffusion magnetic resonance imaging: its 
principles and applications. The Anatomical Record (New Anat.), 257: 102-9. 
 
32 Woodward, P. (2001). MRI for technologists. New York: McGraw-Hill Medical. 408 
pp. 
  
33 Stejskal, E.O. & Tanner, J.E. (1965). Spin diffusion measurements: spin-echo in 
the presence of a time dependent field gradient. J Chem Phys, 42: 288-92. 
 
34 Levitt, M.H. (2008). Spin Dynamics: Basics of Nuclear Magnetic Resonance. 
London: Wiley and Sons. 744 pp. 
 
35 Edelman, R.R., Wielopolski, P., Schmitt, F. (1994). Echo-planar MR imaging. 
Radiology, 192: 600-12. 
 
36 Le Bihan, D., Poupon, C., Amadon, A., & Lethimonnier, F. (2006). Artifacts and 
pitfalls in diffusion MRI. J Magn Reson Imaging, 24 (3): 478-88. 
 
37 Le Bihan D., Breton, E., Lalemand, D., Grenier, P., Cabanis, E., & Laval-Jeantet, 
M. (1986). MR imaging of intravoxel incoherent motions: application to diffusion and 
perfusion in neurologic disorders. Radiology, 161: 401-07. 
 
38 Le Bihan, D. (2003). Looking into the functional architecture of the brain with 
diffusion MRI. Nature Reviews Neuroscience, 4: 469-80. 
   
 
38 
                                                                                                                                       
 
39 Warach, S., Chien, D., Li, W., Ronthal, M., Edelman, R.R. (1992). Fast magnetic 
resonance diffusion-weighted imaging of acute human stroke. Neurology 1992, 42: 
1717-1723. 
 
40 Moseley, M.E., Kucharczyk, J., Mintorovitch, J., Cohen, Y., Kurhanewicz, J., 
Derugin, N., Asgari, H., & Norman, D. (1990). Diffusion-weighted MR imaging of 
acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR 
imaging in cats. AJNR Am J Neuroradiol, 11: 423-429. 
 
41 Latour, L.L., Svoboda, K., Mitra, P.P., & Sotak, C.H. (1994). Time-dependent 
diffusion of water in a biological system. Proc Natl Acad Sci USA, 91: 1229-1233. 
 
42 Hossmann, K.-A., Fischer, M., Bockhorst, K., Hoehn-Berlage, M. (1994). NMR 
imaging of the apparent diffusion coefficient (ADC) for the evaluation of metabolic 
suppression and recovery after prolonged cerebral ischemia. J. Cereb Blood Flow 
Metab., 14: 723-731. 
 
43 Mintorovitch, J., Yang, G.Y., Shimizu, H., Kucharczyk, J., Chan, P.H., & 
Weinstein, P.R. (1994). Diffusion-weighted magnetic resonance imaging of acute 
focal cerebral ischemia: comparison of signal intensity with changes in brain water 
and Na+,K+-ATPase activity. J. Cereb Blood Flow Metab, 14: 723-31. 
 
44 Klatzo, I. (1987). Pathophysiological aspects of brain edema. Acta 
Neuropathologica, 72 (3): 236-39. 
 
45 Knight, R.A., Ordidge, R.J., Helpern, J.A., Chopp, M., Rodolosi, L.C., & Peck, D. 
(1991). Temporal evolution of ischemic damage in rat brain measured by proton 
nuclear magnetic resonance imaging. Stroke, 22: 802-08. 
 
46 Marks, M.P. de Crespigny, A., Lentz, D., Enzmann, D.R., Albers, G.W., & 
Moseley, M.E.  (1996). Acute and chronic stroke: navigated spin-echo diffusion-
weighted MR imaging. Radiology, 199: 403-08. 
 
47 Provenzale, J.M. & Sorensen, A.G. (1999). Diffusion-weighted MR imaging in 
acute stroke: theoretic considerations and clinical applications. AJR Am J 
Roentgenol, 173 (6): 1459-67. 
 
48 Albers, G.W., Lansberg, M.G., Norbash, A.M., Tong, D.C., O’Brien, M.W., 
Woolfenden, A.R., Marks, M.P., & Moseley, M.E. (2000). Yield of diffusion-weighted 
MRI for detection of potentially relevant findings in stroke patients. Neurology, 54: 
1562-67. 
 
49 Bodini, B., & Ciccarelli, O. (2009). Diffusion MRI in neurological disorders. In H. 
Johansen-Berg & T. E.J. Behrens (Eds.), Diffusion MRI: From quantitative 
   
 
39 
                                                                                                                                       
measurement to in vivo neuroanatomy (176-194).  London: Elsevier Academic 
Press. 
 
50 Paviour, D.C., Thornton, J.S., Lees, A.J. & Jager, H.R. (2006). Diffusion-weighted 
magnetic resonance imaging differentiates Parkinsonian variant of multiple-system 
atrophy from progressive supranuclear palsy. Movement Disorders, 22 (1): 68-74. 
 
51 Schocke, M.F.H., Seppi, K., Esterhammer, R., Kremser, C., Jaschke, W., Poewe, 
W., & Wenning, G.K. (2002). Diffusion-weighted MRI differentiates the Parkinson 
variant of multiple system atrophy from PD. Neurology, 58: 575-580. 
 
52 Hanyu, H., Asano, T., Sakurai, H., Imon, Y., Iwamoto, T., Takasaki, M., Shindo, 
H., & Abe, K. (1999). Diffusion-weighted and magnetization transfer imaging of the 
corpus callosum in Alzheimer’s disease. Journal of the Neurological Sciences, 1 (1): 
37-44. 
 
53 Shiga, Y., Miyazawa, K. Sato, S., Fukushima, R., Shibuya, S., Sato, Y., Konno, H., 
Doh-ura, K., Mugikura, S., Tamura, H., Higano, S., Takahashi, S., & Itoyama, Y. 
(2004). Diffusion-weighted MRI abnormalities as an early diagnostic marker for 
Creutzfeldt-Jakob disease. Neurology, 63: 443-49. 
 
54 Rovaris, M., Gass, A., Bammer, R., Hickman, S.J., Ciccarelli, O., Miller, D.H., & 
Fillippi, M. (2005). Diffusion MRI in multiple sclerosis. Neurology, 65: 1526-36. 
 
55 Tsuchiya, K., Katase, S., Yoshino, A., Hachiya, J. (1999). Diffusion-weighted MR 
imaging of encephalitis. Am J Radiol, 173: 1097-99.  
 
56 Yogarajah, M. & Duncan, J.S (2007). Diffusion-based magnetic resonance 
imaging and tractography in epilepsy. Epilepsia, 49 (2): 189-200.  
 
57 Tsuruda, S.J., Chew, M.W., Moseley, E.M., & Norman, D. (1990). Diffusion-
weighted MR imaging of the brain: value of differentiating between extra axial cysts 
and epidermoid tumors. AJNR Am J Neuroradiol, 11: 925-31. 
 
58 Lai, P.H., Ho, J.T., Chen, W.L., Hsu, S.S., Wang, J.S., Pan, H.B., & Yang, C.F. 
(2002). Brain abscess and necrotic brain tumor: discrimination with proton MR 
spectroscopy and diffusion-weighted imaging. AJNR Am J Neuroradiol, 23: 1369-77.  
  
59 Koh, D.M., & Padhani, A.R. (2006). Diffusion-weighted MRI: a new functional 
clinical technique for tumour imaging. Br J Radiol, 79 (944): 633-5. 
 
60 Pauleit, D., Langen K.-J., Floeth, F., Hautzel, H., Riemenschneider, M.J., 
Reifenberger, G., Shah, N.J., & Muller, H.-W. (2004). Can the apparent diffusion 
coefficient be used as a noninvasive parameter to distinguish tumor tissue from 
peritumoral tissue in cerebral gliomas?. J Magn Reson Imaging, 20 (5): 758-64. 
   
 
40 
                                                                                                                                       
 
61 Bulakbasi, N., Guvenc, I., Onguru, O., Erdogan, E., Tayfun, C., & Ucoz, T. (2004). 
The added value of the apparent diffusion coefficient calculation to magnetic 
resonance imaging in the differentiation and grading of malignant brain tumors. J 
Comput Assist Tomogr, 28 (6): 735-46.            
 
62 Kono, K., Inoue, Y., Nakayama, K., Shakudo, M., Morino, M., Ohata, K., Wakasa, 
K., & Yamada, R. (2001). The role of diffusion-weighted imaging in patients with 
brain tumors. AJNR Am J Neuroradiol, 22 (6): 1081-8. 
 
63 Tien, R.D., Felsberg, G.J., Friedman, H., Brown, M., & MacFall, J. (1994). MR 
imaging of high-grade cerebral gliomas: value of diffusion-weighted echo planar 
pulse sequences. AJR Am J Roentgenol, 162: 671-77. 
 
64 Castillo, M., Smith, J.K., Kwock, L., & Wilber, K. (200). Apparent diffusion 
coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J 
Neuroradiol, 22: 60-4. 
 
65 Stadnik, T.W., Chaskis, C., Michotte, A., Shabana, W.M., van Rompaey, K., 
Luypaert, R., Budinsky, L., Jellus, V., Osteaux, M. (2001). Diffusion-weighted MR 
imaging of intracerebral masses: comparison with conventional MR imaging and 
histologic findings. AJNR Am J Neuroradiol, 22 (5): 969-76. 
 
66 Zimmerman, R.D. (2001). Is there a role for diffusion-weighted imaging in patients 
with brain tumors or is the "bloom off the rose"?. AJNR Am J Neuroradiol, 22 (6): 
1013-4. 
 
67 Zacharia, T.T., Law, M., Naidich, T.P., & Leeds, N.E. (2008). Central nervous 
system lymphoma characterization by diffusion-weighted imaging and MR 
spectroscopy. J Neuroimaging, 18 (4): 411-17. 
 
68 Reiche, W., Hagen, T., Schuchardt, V., & Billmann, P. (2007). Diffusion-weighted 
MR imaging improves diagnosis of CNS lymphomas. A report of four cases with 
common and uncommon imaging features. Clin Neurol Neurosurg , 109 (1): 92-101. 
 
69 Guo, A.C., Cummings, T.J., Dash, R.C., & Provenzale, J.M. (2002). Lymphomas 
and high-grade astrocytomas: comparison of water diffusibility and histologic 
characteristics. Radiology, 224 (1): 177-83. 
 
70 Yamasaki, F., Kurisu, K., Satoh, K., Arita, K., Sugiyama, K., Ohtaki, M., Takaba, 
J., Tominaga, A., Hanaya, R., Yoshioka, H., Hama, S., Ito, Y. Kajiwara, Y., Yahara, 
K., Saito, T., & Thohar, M. (2005). Apparent diffusion coefficient of human brain 
tumors at MR imaging. Radiology, 235 (3): pp. 985-91 
 
   
 
41 
                                                                                                                                       
71Toh, C._H., Castillo, M., Wong, A. M.-C., Wei, K.-C., Wong, H.-F., Ng, S.-H., & 
Wan, Y.-L. (2008). Primary cerebral lymphoma and glioblastoma multiforme: 
differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR 
Am J Neuroradiol, 29 (3): 471-5.  
 
72 Horger, M., Fenchel, M., Nagele, T., Moehle, R., Claussen, C.D., Beschorner, R., 
& Ernemann, U (2009). Water diffusivity: comparison of primary CNS lymphoma and 
astrocytic tumor infiltrating the corpus callosum. AJR Am J Roentgenol 193 (5): 
1384-7. 
 
73 Calli, C., Kitis, O., Yunten, N., Yurtseven, T., Islekel, S., & Akalin, T. (2006). 
Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J 
Radiol, 58 (3): 394-403. 
 
74 Al-Okaili, R.N., Krejza, J., Woo, J.H., Wolf, R.L., O’Rourke, D.M., Judy, K.D., 
Poptani, H., & Melhem, E.R. (2007). Intraaxial brain masses: MR imaging-based 
diagnostic strategy--initial experience. Radiology, 243 (2): 539-50. 
 
75 Barajas, R.F., Rubenstein, J.L., Chang, J.S., Hwang, J., & Cha, S. (2010). 
Diffusion-Weighted MR Imaging Derived Apparent Diffusion Coefficient Is Predictive 
of Clinical Outcome in Primary Central Nervous System Lymphoma. AJNR Am J 
Neuroradiol, 31 (1): 60-66. 
 
76 Server, A., Kulle, B., Maehlen, J., Josefsen, R., Schellhorn, T., Kumar, T., 
Langberg, C.W., & Nakstad, P.H. (2009). Quantitative apparent diffusion coefficients 
in the characterization of brain tumors and associated peritumoral edema. Acta 
Radiol, 50 (6): 682-9. 
 
77 Okamoto, K., Ito, J., Ishikawa, K., Sakai, K., & Tokiguchi, S. (2000). Diffusion-
weighted echo-planar MR imaging in differential diagnosis of brain tumors and tumor 
like conditions. Eur Radiol, 10 (8): 1342-50. 
 
78 Sadeghi, N., Camby, I., Goldman, S., Gabius, H.-J., Baleriaux, D., Salmon, I., 
Decaesteckere, C., Kiss, R., & Metens, T. (2003). Effect of hydrophilic components 
of the extracellular matrix on quantifiable diffusion-weighted imaging of human 
gliomas: preliminary results of correlating apparent diffusion coefficient values and 
hyaluronan expression level. AJR Am J Roentgenol, 181 (1): 235-41.  
 
79 Akter, M., Hirai, T., Makino, K., Kitajima, M., Murakami, R., Fukuoka, H., Sasao, 
A., Kuratsu, J.I., & Yamashita, Y. (2008). Diffusion-weighted imaging of primary 
brain lymphomas: effect of ADC value and signal intensity of T2-weighted imaging. 
Comput Med Imaging Graph, 32 (7): 539-43.  
80 DeAngelis LM. Cerebral lymphoma presenting as nonenhancing lesion on 
computed tomographic/magnetic resonance scan. Ann Neurol. 1993;33:308-311. 
 
   
 
42 
                                                                                                                                       
81 Kitis, O., Altay, H., Calli, C., Yunten, N., Akalin, T. & Yurtseven, T. (2005). 
Minimum apparent diffusion coefficients in the evaluation of brain tumors. Eur J 
Radiol, 55 (3): 393-400 
 
82 Camacho, D.L.A., Smith, J.K., Castillo, M. (2003). Differentiation of toxoplasmosis 
and lymphoma in AIDS patients by using apparent diffusion coefficients. AJNR Am J 
Neuroradiol, 24 (4): 633-7. 
 
83 Burdette, J.H., Elster, A.D., & Ricci, P.E. (1998). Calculation of apparent diffusion 
coefficients (ADCs) in brain using two-point and six-point methods. J Comput Assist 
Tomogr., 22(5): 792-4. 
 
84 Provenzale, J.M., Mukundan, S., & Barboriak, D.P. (2006). Diffusion-weighted and 
perfusion MR imaging for brain tumor characterization and assessment of treatment 
response. Radiology, 239(3): 632-49. 
 
85 Koeller, K.K., Smirnitopoulos, J.G., & Jones, R.V. (1997). Primary central nervous 
system lymphoma: radiologic-pathologic correlation. RadioGraphics, 17: 1497-1526. 
 
86 Burstein, S.D., Kernohan, J.W., & Uihlein, A. (1963). Neoplasms of the 
reticuloendothelial system of the brain. Cancer, 16: 289-305. 
 
87 Asao, C., Korogi, Y., Kitajima, M., Hirai, T., Baba, Y., Makino, K., Kochi, M., 
Morishita, S., & Yamashita, Y. (2005). Diffusion-weighted imaging of radiation-
induced brain injury for differentiation from tumor recurrence. AJNR Am J 
Neuroradiol, 26: 1455-60. 
 
88 Al Sayyari, A., Buckely, R., McHenery, C., Pannek, K., Coulthard, A., & Rose, S. 
(2010). Distinguishing recurrent primary brain tumor from radiation injury: a 
preliminary study using a susceptibility-weighted MR imaging-guided apparent 
diffusion coefficient strategy. AJNR Am J Neuroradiol. 
 
89 Smith, J.S., Cha, S., Mayo, M.C., McDermott, M.W., Parsa, A.T., Chang, S.M., 
Dillon, W.P., & Berger, M.S. (2005). Serial diffusion-weighted magnetic resonance 
imaging in cases of glioma: distinguishing tumor recurrence from postresection 
injury. J Neurosurg, 103(3): 428-38. 
 
90 Chenevert, T.L., Stegman, L.D., Taylor, J.M., Robertson, P.L., Greenberg, H.S., 
Rehemtulla, A., Ross, B.D. (2000). Diffusion magnetic resonance imaging: an early 
surrogate marker for therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000, 
92(24): 2029-36. 
 
91 Jain, R., Scarpace, L.M., Ellika, S., Torcuator, R., Schultz, L.R., Hearshen, D., & 
Mikkelsen, T. (2010). Imaging response criteria for recurrent gliomas treated with 
   
 
43 
                                                                                                                                       
bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J 
Neuroncol., 96(3): 423-31. 
 
92 Mardor, Y., Pfeffer, R., Spiegelmann, R., Roth, Y., Maier, S.E., Nissim, O., Berger, 
R., Glicksman, A., Baram, J., Orenstein, A., & Cohen, J.S. (2003). Early detection of 
response to radiation therapy in patients with brain malignancies using conventional 
and high b-value diffusion-weighted magnetic resonance imaging. Journal of Clinical 
Oncology, 21 (6): 1094-1100.  
 
93 Mardor, Y., Roth, Y., Lidar, Z., Jonas, T., Pfeffer, R., Maier, S.E., Meir, F., Nass, 
D., Hadani, M., Orenstein, A., Cohen, J.S., & Ram, Z. (2001). Monitoring response 
to convection-enhanced taxol delivery in brain tumor patients using diffusion-
weighted magnetic resonance imaging. Cancer Research, 61: 4971-73. 
 
94 Ellingson, B.M., Rand, S.D., Malkin, M.G., & Schmainda, K.M. (2010). Utility of 
functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri. J 
Neuroncol., 97 (3): 419-23. 
 
95 Moffat, B.A., Chenevert, T.L., Lawrence, T.S., Meyer, C.R., Johnson, T.D., Dong, 
Q., Tsien, C., Mukherji, S., Quint, D.J., Gebarski, S.S., Robertson, P.L., Junck, L.R., 
Rehemtulla, A., & Ross, B.D. (2005). Functional diffusion map: a noninvasive MRI 
biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci 
U S A., 102 (15): 5524-9. 
 
96 Hamstra, D.A., Galban, C.J., Meyer, C.R., Johnson, T.D., Sundgren, P.C., Tsien, 
C., Lawrence, T.S., Junck, L., Ross, D.J., Rehemtulla, A., Ross, B.D., & Chenevert, 
T.L. (2008). Functional diffusion map as an early imaging biomarker for high-grade 
glioma: correlation with conventional radiologic response and overall survival. J Clin 
Oncol, 26(20): 3387-94. 
 
97 Moseley, M.E., Cohen, Y., Kucharczyk, J., Mintorovitch, J., Asgari, H.S., 
Wendland, M.F., Tsuruda, J., & Norman, D. (1990). Diffusion-weighted MR imaging 
of anisotropic water diffusion in cat central nervous system. Radiology, 176: 439-45. 
 
98 Chenevert, T.L., Brunberg, J.A.,& Pipe, J.G. (1990). Anisotropic diffusion in 
human white matter: demonstration with MR techniques in vivo. Radiology, 177: 
401-05. 
 
99 Stadlbauer, A., Ganslandt, O., Buslei, R., Hammen, T., Gruber, S., Moser, E., 
Buchfelder, M., Salomonowitz, E., & Nimsky, C. (2006). Gliomas: histopathologic 
evaluation of changes in directionality and magnitude of water diffusion at diffusion-




   
 
44 
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Case 8 – lesion ROI 
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